Thierry Chauche - May 6, 2024 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Chief Financial Officer
Signature
/s/ Elizabeth Rozek, Attorney-in-Fact
Stock symbol
SGMT
Transactions as of
May 6, 2024
Transactions value $
$0
Form type
4
Date filed
5/8/2024, 04:06 PM
Previous filing
Apr 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGMT Stock Option (Right to Buy) Award $0 +587K $0.00 587K May 6, 2024 Series A Common Stock 587K $4.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on May 6, 2025, with the remainder vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.